Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SKLB197 is an inhibitor of ataxia-telangiectasia and Rad3-related protein/kinase (ATR) (IC50 = 0.013 µM).1 It is selective for ATR over a panel of 402 other kinases (IC50s = >1 µM). SKLB197 reduces growth in cancer cell lines deficient in ataxia-telangiectasia mutated kinase (ATM; IC50s = 0.13-0.66 µM) to a greater extent than in ATM-expressing cancer cell lines (IC50s = 3.66-8.79 µM). It induces apoptosis in ATM-deficient LoVo colorectal cancer cells but not in ATM-expressing HT-29 colorectal cancer cells and reduces tumor growth in a LoVo mouse xenograft model when administered at doses of 50 or 100 mg/kg.
WARNING This product is not for human or veterinary use.
1. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-